COSCIENS Bio (CSCI) Cash per Single Share

COSCIENS Biopharma Inc. - graphic logo of issuer CSCI

COSCIENS Biopharma Inc. (CSCI) ensures high margins through optimized supply chains for scarce medications. Liquid assets per share reflect reserve dynamics, where the 2.14 metric determines this level. The scientific team is motivated by the financial success of their developments, while a focus on orphan drugs and patent protection shield the company from price wars, guaranteeing a stable market position.

Aeterna Zentaris (CSCI): Cash per Share from 08/10/2024 to 09/14/2025

Analytical breakdowns for COSCIENS Biopharma Inc.

- share price and expert price forecast:
- cash availability and cash flow indicators:
Summary company analysis:CSCI Aeterna Zentaris
Original product of COSCIENS Biopharma

Cash per share determines the portion of liquid capital attributable to a single security by correlating cash flow with the number of shares outstanding. For COSCIENS Biopharma Inc. (CSCI), this metric is 2.14, which is critical when financing early-stage clinical trials prior to the commercialization of the pipeline. By analyzing the free cash flow per share chart, an investor can observe the current margin of safety without reporting time lags. An increase in this metric confirms liquidity, whereas stagnation may indicate accelerating operating expenses.